Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology. It also has a portfolio strategy of potential drug candidates in the form of upfront payments, research payments, milestone payments, and royalties; and investments targeting as sets promoting the green transition. The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity; Camurus' FluidCrystal technology to develop a therapy for hypoparathyroidism; Amylyx Pharmaceuticals to develop a GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases. Gubra A/S was incorporated in 2008 and is headquartered in Horsholm, Denmark.
Frequently asked questions
What sector does Gubra A/S (PI3) operate in?
Gubra A/S belongs to the Other sector and operates in the Biotechnology industry.
What is Gubra A/S (PI3) current stock price?
As of the latest data, Gubra A/S stock price is €38.82, with a previous close of €38.24. Gubra A/S gained €0.58 in the last trading session, representing a 1.52% increase.
What is Gubra A/S (PI3) current market capitalization?
Gubra A/S market cap is approximately 637.38 million.
What is Gubra A/S (PI3) Earnings Per Share (EPS)?
The trailing EPS is -€1.48.
Does Gubra A/S (PI3) pay dividends?
No. Gubra A/S does not pay a dividend.
When is Gubra A/S (PI3) next earnings report?
Gubra A/S is expected to release its next earnings report on September 30, 2026.
What is Gubra A/S (PI3) beta (volatility) score?
Gubra A/S has a beta of 0.310, indicating lower volatility than the overall market.
